| Segment Reporting |
The following table is representative of the significant expense categories regularly provided to the CODM when managing the Company’s single reporting segment. | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | 2026 | | 2025 | | 2026 | | 2025 | Program expenses(1) | | | | | | | | | Atebimetinib (IMM-1-104) | $ | 7,262,339 | | | $ | 5,169,330 | | | $ | 11,317,597 | | | $ | 9,427,266 | | | Envometinib (IMM-6-415) | 18,255 | | | 278,612 | | | 22,600 | | | 1,902,367 | | | Other programs | 2,173,473 | | | 1,172,927 | | | 4,193,338 | | | 2,415,035 | | Non-program expenses(2) | 1,751,748 | | | 1,583,015 | | | 3,221,300 | | | 2,787,399 | | | Employee-related costs | 6,082,231 | | | 4,944,540 | | | 12,150,168 | | | 10,323,479 | | | Stock-based compensation expense | 1,627,909 | | | 1,524,943 | | | 3,264,583 | | | 3,217,210 | | | Depreciation and amortization | 84,454 | | | 84,527 | | | 165,856 | | | 169,788 | | Other segment items(3) | (1,729,982) | | | (324,013) | | | (3,604,121) | | | (762,532) | | | Net loss | $ | 17,270,427 | | | $ | 14,433,881 | | | $ | 30,731,321 | | | $ | 29,480,012 | |
(1) Includes direct research and development expenses. (2) Includes general and administrative expenses, in addition to facilities and other research and development expenses. (3) Includes interest income and other (income) expense.
|